THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.18] ID: TIP-MED-000458 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Micronised Progesterone (Oral / Vaginal Softgel) & Isoxsuprine Hydrochloride

Active Ingredient / Scientific Identity: Micronised Progesterone • Class: Natural Bioidentical Corpus Luteum Progesterone & Beta-Adrenergic Uterine Vasodilator/Tocolytic (Schedule H)

⚖️ Compare Profile
Generic / Entity NameMicronised Progesterone (Oral / Vaginal Softgel) & Isoxsuprine Hydrochloride ([12.18])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassNatural Bioidentical Corpus Luteum Progesterone & Beta-Adrenergic Uterine Vasodilator/Toco
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationSchedule H (Prescription Only — Registered Medical Practitioner)
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H (Prescription Only — Registered Medical P🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Micronised Progesterone (Oral / Vaginal Softgel) & Isoxsuprine Hydrochloride (TIP-MED-000458, Reference Code [12.18]) is classified under Obstetric & Gynaecological Medicines as a Natural Bioidentical Corpus Luteum Progesterone & Beta-Adrenergic Uterine Vasodilator/Tocolytic (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Registered Medical Practitioner).

Verified Indian Market Examples / Compendial Status:
Representative Indian Formulations (for identification only): Micronised Progesterone: Susten (Sun — 100, 200, 300, 400 mg Softgel, 8% Vaginal Gel, IM), Naturogest (Zydus), Hald, Lupigest (Lupin). | Strengths: Micronised Progesterone Softgel Capsules (suitable for Oral, Vaginal, or Rectal insertion!): 100 mg, 200 mg, 300 mg, 400 mg; SR Tablets: 200 mg, 300 mg; Vaginal Gel: 8% (90 mg). Isoxsuprine Tablets: 10 mg IR, 40 mg SR; Injection: 10 mg/2 mL
Representative Indian Formulations (for identification only): Micronised Progesterone: Susten (Sun — 100, 200, 300, 400 mg Softgel, 8% Vaginal Gel, IM), Naturogest (Zydus), Hald, Lupigest (Lupin). | Strengths: Micronised Progesterone Softgel Capsules (suitable for Oral, Vaginal, or Rectal insertion!): 100 mg, 200 mg, 300 mg, 400 mg; SR Tablets: 200 mg, 300 mg; Vaginal Gel: 8% (90 mg). Isoxsuprine Tablets: 10 mg IR, 40 mg SR; Injection: 10 mg/2 mL
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Established pharmacological class action (Natural Bioidentical Corpus Luteum Progesterone & Beta-Adrenergic Uterine Vasodilator/Tocolytic (Schedule H)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Micronised Progesterone: **Luteal Phase Support** in ART/IVF cycles, **Prevention of Preterm Birth** in women with a short cervix (<25 mm on mid-trimester ultrasound) or history of spontaneous preterm birth (**200 mg Vaginal Softgel HS from 16–24 weeks to 36 weeks!**), threatened/recurrent miscarriage, secondary amenor.

4. Therapeutic Indications & Evidence-Supported Uses

  • Micronised Progesterone: **Luteal Phase Support** in ART/IVF cycles, **Prevention of Preterm Birth** in women with a short cervix (<25 mm on mid-trimester ultrasound) or history of spontaneous preterm birth (**200 mg Vaginal Softgel HS from 16–24 weeks to 36 weeks!**), threatened/recurrent miscarriage, secondary amenor

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Micronised Progesterone: **Vaginal Insertion (Luteal Support / Threatened Miscarriage / Short Cervix)**: **200–400 mg inserted high into the vagina ONCE or TWICE DAILY** (Vaginal route delivers a 10-fold higher uterine endometrial concentration via the 'first-uterine-pass effect' while completely avoiding hepatic 5-alp. (Duration: Threatened miscarriage: Up to 12–16 weeks gestation; Short cervix preterm prophylaxis: Up to 36 weeks gestation)

Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified), Topical / Cutaneous | Food & Meal Timing: CRITICAL ROUTE & TIMING RULE FOR MICRONISED PROGESTERONE (SUSTEN / NATUROGEST): The exact same 200 mg softgel capsule can be swallowed OR inserted vaginally! (1) **If prescribed ORALLY**: MUST be take. | Best Time of Day: Oral Progesterone: Strictly at Bedtime (HS). Vaginal Progesterone: Bedtime (OD) or Morning & Bedtime (BD)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Renal: Safe (Vaginal route preferred). Hepatic: Avoid oral route in hepatic impairment (use vaginal route if required)
Elimination & Renal Adjustment:
Renal: Safe (Vaginal route preferred). Hepatic: Avoid oral route in hepatic impairment (use vaginal route if required)
Hepatic Impairment Considerations:
Renal: Safe (Vaginal route preferred). Hepatic: Avoid oral route in hepatic impairment (use vaginal route if required)

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Micronised Progesterone CONTRAINDICATED in active thromboembolism (DVT/PE), severe hepatic dysfunction, breast/genital malignancy, missed/incomplete abortion, and **Peanut / Soya Allergy (check brand excipient — some softgel capsules use arachis/peanut oil or soy lecithin suspension!)**

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Micronised Progesterone: **Oral route**: Marked drowsiness, dizziness/vertigo (15–25% within 1–3h of swallowing!), headache, breast tenderness
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CYP3A4 inducers (Rifampicin, Carbamazepine, Phenytoin) accelerate Progesterone clearance
  • Vaginal antifungal creams (Clotrimazole/Miconazole pessaries) should not be inserted simultaneously with Vaginal Progesterone softgels (reduces progesterone release from the lipid base!)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • THREE VITAL OBSTETRIC COUNTER RULES FOR SUSTEN / NATUROGEST: (1) **Always clarify the route**: the box says 'For Oral / Vaginal / Rectal Use' — for pregnancy support, doctors usually want the softgel **inserted deep into the vagina** (which goes straight to the womb with zero dizziness), whereas if swallowed by mouth it must be taken **on

Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Micronised Progesterone Softgel Capsules (suitable for Oral, Vaginal, or Rectal insertion!): 100 mg, 200 mg, 300 mg, 400 mg; SR Tablets: 200 mg, 300 mg; Vaginal Gel: 8% (90 mg). Isoxsuprine Tablets: 10 mg IR, 40 mg SR; Injection: 10 mg/2 mL). Missed-Dose Rule: Insert/take as soon as remembered

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.